(Q43871127)

27 November 2017

title

Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases (English)

1 reference

27 November 2017

0 references

phase II clinical trial

0 references

phase I clinical trial

0 references

author name string

Grüschow K

series ordinal

1

1 reference

27 November 2017

Klautke G

series ordinal

2

1 reference

27 November 2017

Fietkau R

series ordinal

3

1 reference

27 November 2017

publication date

1 February 2002

1 reference

European Journal of Cancer

27 November 2017

published in

1 reference

27 November 2017

volume

38

1 reference

27 November 2017

issue

3

1 reference

27 November 2017

page(s)

367-374

1 reference

Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Chemotherapy for brain metastases of lung cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Topotecan--a new treatment option in the therapy of brain metastases of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Chemotherapy of brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

A randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900373-2

7 January 2021

10.1016/S0959-8049(01)00373-2

Identifiers

DOI

1 reference

27 November 2017

1 reference